KRAS mutant circulating free DNA (cfDNA) in peripheral blood as a biomarker in patients diagnosed with pancreatic ductal adenocarcinoma

Introduction: The key to improving prognosis in PDAC may lie in early detection of the disease although there are few reliable markers to check for microscopic metastatic or residual disease.

Saved in:
Bibliographic Details
Published inPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] Vol. 15; no. 3; p. S91
Main Authors Earl, Julie, Garcia-Nieto, Sandra, Martinez-Avila, Jose Carlos, Montans, José, Sanjuanbenito, Alfonso, Rodríguez-Garrote, Mercedes, Lisa, Eduardo, Mendía, Elena, Lobo, Eduardo, Malats, Núria, Carrato, Alfredo, Guillen-Ponce, Carmen
Format Journal Article
LanguageEnglish
Published Philadelphia Elsevier B.V 01.06.2015
Elsevier Limited
Subjects
Deoxyribonucleic acid
DNA
Endocrinology & Metabolism
Gastroenterology and Hepatology
Medical prognosis
Mutation
Ovarian cancer
Tumors
Online AccessGet full text

Cover

More Information
Summary:Introduction: The key to improving prognosis in PDAC may lie in early detection of the disease although there are few reliable markers to check for microscopic metastatic or residual disease.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2015.05.333